REGN — Regeneron Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $99.30bn
- $91.16bn
- $13.12bn
- 94
- 32
- 86
- 81
Annual cashflow statement for Regeneron Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2,116 | 3,513 | 8,075 | 4,338 | 3,954 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 435 | 297 | 783 | 1,325 | 1,151 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -201 | -1,504 | -1,917 | -243 | -94.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 2,430 | 2,618 | 7,081 | 5,015 | 4,594 |
| Capital Expenditures | -430 | -615 | -552 | -1,617 | -926 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -1,598 | 544 | -4,833 | -2,168 | -2,259 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -2,028 | -70.6 | -5,385 | -3,785 | -3,185 |
| Financing Cash Flow Items | -188 | -681 | -1,033 | -446 | -701 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -252 | -1,971 | -1,006 | -1,009 | -1,790 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 150 | 577 | 691 | 221 | -382 |